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receiving the interventions. If other important policy considerations might facilitate or hinder 
the implementation, these are raised. 
This approach is not fully informative for two reasons. First, some interventions appear cost-
effective when analysed in isolation but have more efficient alternatives. Second, the one-by-
one analyses do not take into account that many interventions are not implemented in 
isolation. When combinations of interventions are analysed, care must be taken not to 
double-count shared costs and benefits. The latter tends to be the more important 
consideration: other interventions in the chosen package reduce disease rates and any 
additional interventio  cannot claim the same reduction. The pamphl ts o  pecific topic 
areas (such as blood pressure and cholesterol-lowering, alcohol, physical inactivity, body 
mass and kidney disease) present the most cost-effective ‘optimal’ mix to address a health 
problem. Another pamphlet shows the combined impact of the most cost-effective prevention 
intervention options across all topic areas.  
 
3. League table categories 
For clarity of presentation, we have ‘triaged’ our cost-effectiveness results into five categories 
and then within each category reported on broader issues that impact on policy decisions. In 
ACE–Prevention we assume a decision threshold of ‘$50,000 per DALY prevented’ to 
determine whether an intervention is ‘cost-eff ctiv ’ o  not. The categories are:  
• Dominant: interventions that both improve health and achieve net cost savings;  
• Very Cost-Effective: interventions that improve health at a cost of less than $10,000 per 
DALY prevented;  
• Cost-Effective: interventions that improve health at a cost of between $10,000 and 
$50,000 per DALY prevented;  
• Not Cost-Effective: interventions that improve health at a cost of more than $50,000 per 
DALY prevented; and  
• Dominated: interventions for which more cost-effective alternatives are available.  
Th  results for 123 preventive interventions evalu ted r  classifie  by triage category. Full 
documentation (including treatment interventions and multiple variations of some 
interventions) are provided in Appendix 2 of the main report. The following is the key to 
reading the results tables: 
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Table 1:  Lifetime health outcomes, intervention costs and cost offsets for the most cost-effective 
preventive interventions with the largest population health impact 
 (Lifetime, discounted)  






Taxation    
Tobacco tax 30% 270,000 0.02 –0.7 
Alcohol tax 30% 100,000 0.02 –0.5 
Alcohol volumetric tax 10% above current 
excise on spirits 110,000 0.02 –0.7 
Unhealthy foods tax 10% 170,000 0.02 –3.5 
Regulation    
Mandatory salt limits on processed food 110,000 0.07 –1.5 
Preventive treatments    
Three blood-pressure-lowering drugs to 
replace current practice of preventive drug 
treatments* 
20,000 –1.9† –0.3 
Polypill to replace current practice*  60,000 –7.0† –0.8 
Laparoscopic gastric banding (body mass 
index >35) 140,000 3.7 –2.9 
Health promotion    
Intensive SunSmart  120,000 2.0 –0.3 
 
DALY, disability-adjusted life year 
*  estimate a lif time h alth benefit of 230,000 DALYs p vented from current practice. The p lypill or a 
combination of blood-pressure-lowering drugs targeting by absolute cardiovascular disease risk and ‘realistic’ 
assumptions on uptake and adherence would lead to large cost savings and some greater health gain additional 
to the 230,000 DALYs of current practice (hence we classify these as interventions with a large impact greater 
than 100,000 lifetime DALYs). 
† The current practice of blood pressure- and cholesterol-lowering treatments is inefficient and hence the negative 





























4.2  results classified By cost-effectiVeness ratio










Table 2: Dominant (cost-saving) preventive interventions for non-communicable disease, ACE-
Prevention 








Alcohol Volumetric tax ++ + Likely 
 Tax increase 30% +++ + Likely 
 Advertising bans + + Limited 
 Raise minimum legal drinking age to 21 + + Limited 
Tobacco Tax increase 30% (with or without indexation) +++ + Likely 
Physical activity Pedometers ++ ++ Sufficient 
Mass media ++ ++ Inconclusive 
Nutrition Community fruit and vegetable intake 
promotion 
+ ++ May be effective 
 Voluntary salt limits + + Likely 
 Mandatory salt limits +++ + Likely 
Body mass 10% tax on unhealthy food +++ + May be effective 
Blood pressure 
and cholesterol 
Community heart health program ++ + May be effective 
Polypill $200 for >5% CVD risk +++ +++ Likely 
Osteoporosis  Screen women age 70+ and alendronate ++ ++ Sufficient 
Hepatitis B Vaccine and immunoglobulin to infants born to 
carrier or high-risk mothers 
+ + Sufficient 
 High-risk infant vaccination + + Sufficient 
 Selective vaccination of infants with mothers 
from highly endemic countries 
+ + Sufficient 
Kidney disease Proteinuria screen and ACE inhibitors for 
diabetics 
++ + Sufficient 
Mental 
disorders 
Problem-solving post-suicide attempt + + Sufficient 
Treatment for individuals at ultra-high risk for 
psychosis 
+ + Likely 
Oral health Fluoridation drinking water, non-remote  + + Limited 
 











































Table 3 Very cost-effective preventive interventions ($0–10,000 per DALY) for non-communicable disease, 
ACE–Prevention  








Alcohol Brief alcohol intervention GP with or without 
telemarketing and support 
+ + Sufficient 
 Licensing controls + + Likely 
Tobacco Cessation aid: varenicline ++ +++ Sufficient 
 Cessation aid: bupropion ++ +++ Sufficient 
 Cessation aid: nicotine replacement therapy ++ ++ Sufficient 
Physical activity GP Green Prescription + +++ Limited 
 Internet intervention + ++ Sufficient 
Nutrition Information mail-out, multiple re-tailored to 
promote fruit and vegetable intake 
+ + Limited 
Body mass Gastric banding for severe obesity +++ +++ Sufficient 
Blood pressure 
and cholesterol 
Low-dose diuretics >5% CVD risk +++ +++ Sufficient 
Polypill $200 to ages55+ +++ +++ Likely 
CCBs >10% CVD risk ++ ++ Sufficient 
 ACE inhibitors >15% CVD risk ++ ++ Sufficient 
Mental disorders 
drugs/suicide 
Screen and bibliotherapy to prevent adult 
depression  
+ ++ Likely 
Screen and psychologist to prevent 
childhood/adolescent depression 
+ ++ Sufficient 
 Screen and bibliotherapy to prevent 
childhood/adolescent depression 
+ + Limited 
 Responsible media reporting for the reduction of 
suicide 
+ + Likely 
 Parenting intervention for the prevention of 
childhood anxiety disorders 
+ + Sufficient 
Other Universal infant HBV vaccination + ++ Sufficient 
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; CVD, cardiovascular disease; HBV, 























Table 4  Cost-effective preventive interventions ($10,000–50,000 per DALY) for non-communicable 
disease, ACE-Preve tion 








Alcohol Drink drive mass media + ++ Limited 
 Roadside breath testing + ++ Likely 
Physical activity TravelSmart + +++ May be 
effective 
 GP referral + +++ Limited 
Nutrition Multiple tailored mailed fruit and vegetable 
promotion 
+ + Limited 
Obesity Diet and exercise for overweight + +++ Sufficient 
 Low-fat diet for overweight + ++ Sufficient 
Blood pressure 
and cholesterol 
Dietary counselling >5% CVD risk by dietitian ++ ++ Sufficient 
Dietary counselling >5% CVD risk by GP ++ ++ Sufficient 
 Phytosterol supplementation >5% CVD risk ++ +++ Sufficient 
 Statins >5% CVD risk +++ +++ Sufficient 
 Statins and ezitimibe >5% CVD risk +++ +++ Sufficient 
 Beta blockers >5% CVD risk ++ +++ Sufficient 
 CCBs >5% CVD risk +++ +++ Sufficient 
 ACE inhibitors >5% CVD risk +++ +++ Sufficient 
Cancer Pap screen (current practice) + ++ Sufficient 
 HPV DNA test screen 3-yearly from age 18 + + Likely 
 HPV vaccination and Pap screen  + ++ Likely 
 HPV vaccination and HPV DNA test screen 3-
yearly from age 18 
+ ++ Likely 
 SunSmart +++ +++ Limited 
Pre-diabetes Screen and dietary advice + ++ Sufficient 
 Screen and exercise physiologist ++ ++ Sufficient 
 Screen and diet + exercise  ++ ++ Sufficient 
 Screen and metformin ++ ++ Sufficient 
 Screen and acarbose ++ ++ Sufficient 
Kidney disease Screen and ACE-inhibitors for non-diabetics 
age >25  
++ ++ Sufficient 
Mental disorders Screen and group CBT to prevent adult 
depression 
+ ++ Likely 
Screen and CBT to prevent post-partum 
depression 
+ + Limited 
ACE, angiotensin-converting enzyme; CBT, cognitive behaviour therapy; CCB, calcium channel blocker; CVD, 




























Table 5  Cost-ineffective preventive interventions (>$50,000 per DALY) for non-communicable disease, 
ACE-Prevention 
Topic area Intervention Comments 
Diet Fruit and vegetable interventions targeting 
individuals (except tailored mailings) 
Poor effectiveness 
  Fruit and vegetable interventions at workplace Poor effectiveness 
  Dietary advice on salt Poor effectiveness and high cost 
  Weight Watchers Poor maintenance of weight loss 
  Multi-component diet/physical activity/weight 
intervention 
Poor effectiveness 
  Orlistat, sibutramine Too expensive 
Osteoporosis Raloxifene No effect on hip fractures and too 
expensive 
Cancer Combined Pap and HPV DNA test screen 3-
yearly from age 18 
No benefit from start at age 18 
instead of 25 
 HPV vaccination and combined Pap and HPV 
DNA test screen 3-yearly from age 18 
No benefit from start at age 18 
instead of 25 
 Anal cytology for MSM Expensive screen for rare cancer 
Pre-diabetes Screen and orlistat Too expensive 
 Screen and rosiglitazone Too expensive 
CVD Aspirin Risk of bleeding and ambiguous 
evidence for effect in primary 
prevention 






School-based drug intervention Poor effectiveness 
Gun buy-back and legislation changes to reduce 
suicides 
Only ecological evidence for 
reduction in suicide; high cost 
Shingles Varicella zoster vaccination at age 50 Low frequency of shingles; 
expensive 








Table 6 Dominated interventions, ACE-Prevention 
Topic area Intervention Comments 
Cancer Prostate cancer screen by PSA More harm than benefit 
Diabetes Screen and rosiglitazone Adverse effect on cardiovascular 
disease 
Blood pressure and 
cholesterol 
Beta blockers Three more efficient drugs in class 
Dietary advice by a GP Less expensive option 







Table 5  Cost-ineffective preventive interventions (>$50,000 per DALY) for non-communicable disease, 
ACE-Prevention 
Topic area Intervention Comments 
Diet Fruit and vegetable interventions targeting 
individuals (except tailored mailings) 
Poor effectiveness 
  Fruit and vegetable interventions at workplace Poor effectiveness 
  Dietary advice on salt Poor effectiveness and high cost 
  Weight Watchers Poor maintenance of weight loss 
  Multi-component diet/physical activity/weight 
intervention 
P or effectiveness 
  Orlistat, sibutramine T o xpensive 
Osteoporosis Raloxifene No effect on hip fractures and too 
expensive 
Cancer Combined Pap and HPV DNA test screen 3-
yearly from age 18 
No benefit from start at age 18 
instead of 25 
 HPV vaccination and combined Pap and HPV 
DNA test screen 3-yearly from age 18 
No benefit from start at age 18 
instead of 25 
 nal cytology for MSM Expensiv  screen for rare cancer 
Pre-diabetes Screen and orlistat Too expensive 
 Screen and rosiglitazone Too expensive 
CVD Aspirin Risk of bleeding and ambiguous 
evidence for effect in primary 
prevention 






School-based drug intervention Poor effectiveness 
Gun buy-back and legislation changes to reduce 
suicides 
Only ecological evidence for 
reduction in suicide; high cost 
Shingles Varicella zoster vaccination at age 50 Low frequency of shingles; 
expensive 








Table 6 Dominated interventio s, ACE-Prevention 
Topic area Intervention Comments 
Cancer Prostate cancer screen by PSA More harm than benefit 
Diabetes Screen and rosiglitazone Adverse effect on cardiovascular 
disease 
Blood pressure and 
cholesterol 
Beta blockers Three more efficient drugs in class 
Dietary advice by a GP Less expensive option 








To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies 
standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking a health 
sector perspective. This information is intended to help decision-makers move resources from less efficient current 
practices to more efficient preventive action resulting in greater health gain for the same outlay.
Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
paMpHlets in tHis series 
Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 















14. Renal replacement therapy, screening and early treatment of chronic kidney disease
15. Salt
16. Suicide prevention
17. Tobacco 
